VYNE Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements Of Operations and Comprehensive Loss
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(U.S. dollars and share data in thousands, except per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues | ||
| Royalty revenues | $86 | $202 |
| Total revenues | 86 | 202 |
| Operating expenses: | ||
| Research and development | 817 | 6,124 |
| General and administrative | 3,085 | 3,275 |
| Total operating expenses | 3,902 | 9,399 |
| Operating loss | (3,816) | (9,197) |
| Other income, net | 231 | 594 |
| Loss from continuing operations before income taxes | (3,585) | (8,603) |
| Income tax expense | — | — |
| Loss from continuing operations | (3,585) | (8,603) |
| Loss from discontinued operations, net of income taxes | — | (8) |
| Net loss | $(3,585) | $(8,611) |
| Loss per share from continuing operations, basic and diluted | $(0.08) | $(0.20) |
| Loss per share from discontinued operations, basic and diluted | $— | $— |
| Loss per share, basic and diluted | $(0.08) | $(0.20) |
| Weighted average shares outstanding - basic and diluted | 42,768 | 42,673 |
| Other comprehensive loss: | ||
| Unrealized losses on marketable securities, net of tax of $0 | (2) | (20) |
| Total other comprehensive loss | (2) | (20) |
| Comprehensive loss | $(3,587) | $(8,631) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.